Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Midazolam Clear all
Completed Phase 1 Interventional Results available

A Study of Ixekizumab in Participants With Plaque Psoriasis

NCT02993471
View directory record Official record
Conditions
Psoriasis
Interventions
Drug Cocktail, Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 19, 2026, 3:13 PM EDT
Not listed Phase 4 Interventional

Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

NCT04049786
View directory record Official record
Conditions
Obesity, Bariatric Surgery, Roux-en Y Gastric Bypass
Interventions
Digestive biopsy, Carvedilol 25mg, Serial blood sampling for PK analysis, Metoprolol 100 mg for CYP2D6 phenotyping, Simvastatin 40mg, Midazolam 2 mg for CYP3A4 phenotyping, Genotyping
Procedure · Drug · Other
Lead sponsor
Natalia Valadares de Moraes
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 19, 2026, 3:13 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

NCT01529034
View directory record Official record
Conditions
Epilepsy
Interventions
USL261
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

NCT06186622
View directory record Official record
Conditions
Healthy, Obese, Overweight
Interventions
Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam, Sodium Bicarbonate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

NCT03762928
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06651600, midazolam, efavirenz
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Understanding How Ketamine Brings About Rapid Improvement in OCD

NCT02624596
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 3:13 PM EDT
Completed No phase listed Observational

Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents

NCT01976078
View directory record Official record
Conditions
Pharmacokinetics, Voriconazole
Interventions
Midazolam/Ranitidine/Esomeprazole
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Personalizing Preprocedural Sedation for Regional Anesthesia

NCT05579509
View directory record Official record
Conditions
Catastrophizing Pain
Interventions
Midazolam and Fentanyl, Educational Reassurance
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 19, 2026, 3:13 PM EDT
Terminated Phase 4 Interventional

Regional Erector Spinae Analgesic Block vs Standard of Care Undergoing Percutaneous Nephrolithotomy

NCT04663269
View directory record Official record
Conditions
Kidney Stone, Surgery
Interventions
4mg PF Dexamethasone, Control Test
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

NCT02578277
View directory record Official record
Conditions
HIV Infections
Interventions
CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

NCT03187496
View directory record Official record
Conditions
NASH
Interventions
Midazolam, Caffeine, Rosuvastatin, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Not applicable Interventional Results available

Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion

NCT03187002
View directory record Official record
Conditions
Abortion in First Trimester
Interventions
Transcutaneous electrical nerve stimulation (TENS), Moderate IV Sedation, SHAM: Transcutaneous electrical nerve stimulation (TENS), SHAM: Moderate IV Sedation
Device · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 19, 2026, 3:13 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

NCT00504413
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
midazolam(drug), digoxin (drug), Bupropion (drug), Methadone (drug)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

NCT02567682
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

NCT02461160
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 19, 2026, 3:13 PM EDT
Completed No phase listed Observational

Ketamine Versus Midazolam for Prehospital Agitation

NCT03554915
View directory record Official record
Conditions
Agitation
Interventions
Ketamine-based protocol, Midazolam-based protocol
Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis

NCT05530278
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Galicaftor, ABBV-576, Navocaftor, Midazolam
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

NCT02607774
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
Midazolam, AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 4 Interventional Results available

Ketamine For Suicidal Ideation

NCT01507181
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department

NCT03085563
View directory record Official record
Conditions
Conscious Sedation, Simple Lacerations Less Than 4 cm, Lumbar Punctures, Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement
Interventions
Nitrous Oxide, Midazolam
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 19, 2026, 3:13 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The RECAP2 Study: Midazolam and Psilocybin

NCT06692192
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Midazolam, Saline
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 3:13 PM EDT
Active, not recruiting Phase 2 Interventional

Ketamine for Multiple Sclerosis Fatigue

NCT05378100
View directory record Official record
Conditions
Multiple Sclerosis Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 19, 2026, 3:13 PM EDT
Completed Phase 1 Interventional

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

NCT02520752
View directory record Official record
Conditions
cMET-dysregulated Advanced Solid Tumors
Interventions
INC280, Midazolam, Caffeine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 19, 2026, 3:13 PM EDT
Terminated Not applicable Interventional Results available

Infrared Pupillometry During General Anesthesia to Predict Pain

NCT02058511
View directory record Official record
Conditions
Postoperative Pain, Objective Assessment of Sedation
Interventions
Anesthesia Premedication, Induction and Maintenance, Pupillometry after administration of anesthetic drugs
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 19, 2026, 3:13 PM EDT